{"id":839299,"date":"2025-04-21T07:33:33","date_gmt":"2025-04-21T11:33:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/"},"modified":"2025-04-21T07:33:33","modified_gmt":"2025-04-21T11:33:33","slug":"anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/","title":{"rendered":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  21, 2025  (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex\u2019s Scientific Advisory Board gave an oral presentation titled, \u201c<em>Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb\/III Trial<\/em>\u201d at the 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East.<\/p>\n<p align=\"justify\">The \u20189th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East\u2019 was held April 18-20, 2025 in Abu Dhabi, United Arab Emirates (UAE). The meeting convened clinicians including neurologists, psychiatrists, and geriatricians, nurses, public health workers, researchers, social workers, students, caregivers, and community advocates from the Middle East and North Africa (termed the MENA region), USA, Europe and other countries with an interest in epidemiology, clinical\/research, medicine, basic science, and healthcare advocacy related to Alzheimer\u2019s disease and related disorders (ADRD) in the region. Specifically, an emphasis on region specific healthcare delivery were addressed.<\/p>\n<p align=\"justify\">This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.<\/p>\n<p>\n        <strong>About Anavex Life Sciences Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex&#8217;s lead drug candidate, ANAVEX<sup>\u00ae<\/sup>2-73 (<em>blarcamesine<\/em>), has successfully completed a Phase 2a and a Phase 2b\/3 clinical trial for Alzheimer&#8217;s disease, a Phase 2 proof-of-concept study in Parkinson&#8217;s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2\/3 study in pediatric patients with Rett syndrome. ANAVEX<sup>\u00ae<\/sup>2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and\/or reverse the course of Alzheimer&#8217;s disease. ANAVEX<sup>\u00ae<\/sup>2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson&#8217;s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX<sup>\u00ae<\/sup>2-73 for the treatment of Parkinson&#8217;s disease. We believe that ANAVEX<sup>\u00ae<\/sup>3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX<sup>\u00ae<\/sup>3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QT2U8He5kQo_CUnCuzKnyNC49NFcZfneFCRnUuKO9or49TKiY2RhZPK0X7VTua9LjOJNpaW6HQ90UBtozejWUA==\" rel=\"nofollow\" target=\"_blank\">www.anavex.com<\/a>. You can also connect with the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nYfQ7kgVJH3RCuHE31oPCrwGanWpnMItto9XiuK0l3-S4ACyeen59GWTvIUrz-qGz9RluC-mdjNLlTPtc9NHw4dFXIh9hff9oQhq5eB1A4E=\" rel=\"nofollow\" target=\"_blank\">Twitter,<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hmTd3VLiAi-JfwtZ6u_1dUDkajDUwG0JJxIx0rP_qou8DHO12zYqX9jq962kpJ1g6cEeKb7m8hrCy3Llp15WyBXB39VYDUCJk3Lb6YzFekNpQEFW62FgIBXxWcIWh40aIeLNEV9FKPxLmpgTYIsVRQ==\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-oxxbBgqEu91EcaVCUSGDT9bXiU5OBfJkVMxYMDGNzYQtSNiiWJBUf8-hjeOSBPE8t75mdWM5mrJB3UG77XX-TVu_J1-94irnpP20HlzGjc=\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=22G3xTkt4jjTXXJUFJO6BooDctxPRjBCAP8YlgsL_uIL6oPT_U--lrBs1u5R6ZE3n0NgAYFQhwObTOI1Gr5TsVCyFXKN6sbF84gc6P9hS5TS7ebYG6uCNREgv_BkPEaj\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company\u2019s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.<\/p>\n<p align=\"justify\">\n        <strong>For Further Information:<\/strong><br \/>\n        <br \/>Anavex Life Sciences Corp.<br \/>Research &amp; Business Development<br \/>Toll-free: 1-844-689-3939<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8kWXw3Jh6H5M718xLM1r1TlKrWmw5dBy5FZruo_oBdphNU3bj2_OAqVWRIWVTD919prAoozCCngDwZ4MR8WCUQ==\" rel=\"nofollow\" target=\"_blank\">info@anavex.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Andrew J. Barwicki<br \/>Investor Relations<br \/>Tel: 516-662-9461<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9EluY0SAbCefpDClTIclE1IaQXqtPVhSG47NBC_TWWj7KsJlOyvUil0J1CgpPvswC-d-ZueE-pkN7dMxckhPw-VwKZTM7QPbypu_yQi0XH8=\" rel=\"nofollow\" target=\"_blank\">andrew@barwicki.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OWI4MjNiNjgtN2RmMC00OWI2LWIwM2EtZjc0ZjQyNjY4OWMzLTEwMzExNzYtMjAyNS0wNC0yMS1lbg==\/tiny\/Anavex-Life-Sciences-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex\u2019s Scientific Advisory Board gave an oral presentation titled, \u201cOral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb\/III Trial\u201d at the 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East. The \u20189th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-839299","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex\u2019s Scientific Advisory Board gave an oral presentation titled, \u201cOral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb\/III Trial\u201d at the 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East. The \u20189th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle &hellip; Continue reading &quot;Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T11:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East\",\"datePublished\":\"2025-04-21T11:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/\",\"name\":\"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\",\"datePublished\":\"2025-04-21T11:33:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/","og_locale":"en_US","og_type":"article","og_title":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk","og_description":"NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (\u201cAnavex\u201d or the \u201cCompany\u201d) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer&#8217;s disease, Parkinson&#8217;s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex\u2019s Scientific Advisory Board gave an oral presentation titled, \u201cOral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb\/III Trial\u201d at the 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East. The \u20189th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle &hellip; Continue reading \"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-21T11:33:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East","datePublished":"2025-04-21T11:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/"},"wordCount":695,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/","name":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=","datePublished":"2025-04-21T11:33:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzNTM2OSM2ODk1MTQ2IzIwMTk1Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/anavex-life-sciences-announces-presentation-at-9th-international-conference-on-alzheimers-disease-and-related-disorders-in-the-middle-east\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer\u2019s Disease and Related Disorders in the Middle East"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=839299"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839299\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=839299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=839299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=839299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}